These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22257100)

  • 21. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabazitaxel in metastatic castration-resistant prostate cancer.
    Yap TA; Pezaro CJ; de Bono JS
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1129-36. PubMed ID: 23098113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
    Armstrong AJ; Tannock IF; de Wit R; George DJ; Eisenberger M; Halabi S
    Eur J Cancer; 2010 Feb; 46(3):517-25. PubMed ID: 20005697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 25. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
    Schutz FA; Buzaid AC; Sartor O
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the management of high-risk localised and metastatic prostate cancer.
    Bellmunt J; Attard G; Bahl A; Huland H; Klotz L; Kuban D; Oudard S; Watson W
    BJU Int; 2012 Mar; 109 Suppl 2():8-13. PubMed ID: 22257099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
    Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
    Sonpavde G; Wang CG; Galsky MD; Oh WK; Armstrong AJ
    BJU Int; 2015 Jul; 116(1):17-29. PubMed ID: 25046451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
    Eymard JC; Oudard S; Gravis G; Ferrero JM; Theodore C; Joly F; Priou F; Krakowski I; Zannetti A; Thill L; Beuzeboc P
    BJU Int; 2010 Oct; 106(7):974-8. PubMed ID: 20230389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of metastatic prostate cancer: the crucial role of geriatric assessment.
    Droz JP; Chaladaj A
    BJU Int; 2008 Mar; 101 Suppl 2():23-9. PubMed ID: 18307689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Castration-resistant prostate cancer: where are we going?].
    Alcaraz A; Medina R; Maroto P; Climent MÁ; Castellano D; Carles J
    Actas Urol Esp; 2012 Jun; 36(6):367-74. PubMed ID: 22188754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
    Sartor O; Halstead M; Katz L
    Clin Genitourin Cancer; 2010 Dec; 8(1):23-8. PubMed ID: 21208852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
    ; Berry DL; Moinpour CM; Jiang CS; Ankerst DP; Petrylak DP; Vinson LV; Lara PN; Jones S; Taplin ME; Burch PA; Hussain MH; Crawford ED
    J Clin Oncol; 2006 Jun; 24(18):2828-35. PubMed ID: 16782921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line therapy for castrate-resistant prostate cancer: a literature review.
    Kao SC; Hovey E; Marx G
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):212-23. PubMed ID: 21884433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.